Panacea Biotec Surges 17% on UNICEF Vaccine Orders

• Panacea Biotec stock jumped over 17% today, defying a broader market decline.
• The small-cap pharma company secured new and expanded vaccine supply contracts from UNICEF.
• Additional orders for pentavalent vaccine (Easyfive-TT) total $8.9 million (₹80 crore) for 2027.
• Previously, UNICEF awarded a $35.65 million (₹315 crore) long-term order for bOPV, for 2026-2030.
• These orders strengthen Panacea Biotec's global vaccine supply and revenue visibility for 2026-2027.

Why It Matters: UNICEF vaccine orders boost Panacea Biotec's stock and future revenue visibility.